Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could early treatment tame a painful skin condition?

NCT ID NCT07690319

Not yet recruiting Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study looks at whether starting secukinumab early in people with moderate-to-severe hidradenitis suppurativa (a chronic skin condition causing painful lumps) can slow disease progression. Researchers will analyze data from existing medical records and registries across Europe. The goal is to see if early action leads to better outcomes, such as a 55% reduction in disease severity at 6 and 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
secukinumab
What this could lead to
If early treatment proves effective, it could help reduce long-term disease severity and improve quality of life for people with hidradenitis suppurativa.
What could go wrong
This is an observational study using existing data, not a controlled trial, so results may be less reliable. Secukinumab can have side effects like infections or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIDRADENITIS SUPPURATIVA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.